Literature DB >> 15491232

A clinical perspective of attention-deficit/hyperactivity disorder into adulthood.

Timothy E Wilens1, William Dodson.   

Abstract

OBJECTIVE: Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder that affects all age groups. Recent data on the clinical presentation, comorbidity, neurobiology, and treatment are reviewed.
METHOD: Using the search term ADHD, a selective PubMed review of the clinical literature was undertaken to evaluate recent data relevant to ADHD with attention to a life span perspective of the disorder.
RESULTS: A growing literature indicates that ADHD is more persistent than previously thought and has a developmental variability in its presentation. The disorder impairs academic, social, and occupational functioning and is often associated with comorbidity, including cigarette smoking and substance abuse. Considerable evidence suggests that the disorder has a strong genetic component and a biological underpinning; the pathophysiology includes dysfunction in both noradrenergic and dopaminergic systems. Both psychosocial therapy and pharmacotherapy have been shown effective in the treatment of the disorder throughout the life span. The therapeutic effectiveness of pharmacologic agents in the treatment of ADHD has been attributed to noradrenergic and/or dopaminergic effects.
CONCLUSION: ADHD is associated with impairment and comorbidity throughout the life span. Growing evidence suggests the importance of short- and long-term management of the disorder. While the long-term treatment of ADHD is expected to lessen the individual's impairment, the outcome for adults who have received treatment since childhood requires further study.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15491232     DOI: 10.4088/jcp.v65n1003

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  39 in total

1.  Adverse effects of heavy prenatal maternal smoking on attentional control in children with ADHD.

Authors:  Maria G Motlagh; Denis G Sukhodolsky; Angeli Landeros-Weisenberger; Liliya Katsovich; Nancy Thompson; Lawrence Scahill; Robert A King; Bradley S Peterson; Robert T Schultz; James F Leckman
Journal:  J Atten Disord       Date:  2010-07-08       Impact factor: 3.256

Review 2.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

Review 3.  Recommendations for the use of pharmacological smoking cessation strategies in pregnant women.

Authors:  Tim Coleman
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Validation of the adult attention-deficit/hyperactivity disorder quality-of-life Scale (AAQoL): a disease-specific quality-of-life measure.

Authors:  Meryl Brod; Joseph Johnston; Stephen Able; Ralph Swindle
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

5.  Growing up with epilepsy: a two-year investigation of cognitive development in children with new onset epilepsy.

Authors:  Bruce P Hermann; Jana E Jones; Raj Sheth; Monica Koehn; Tara Becker; Jason Fine; Chase A Allen; Michael Seidenberg
Journal:  Epilepsia       Date:  2008-09-10       Impact factor: 5.864

6.  Association of the glutamate receptor subunit gene GRIN2B with attention-deficit/hyperactivity disorder.

Authors:  K M Dorval; K G Wigg; J Crosbie; R Tannock; J L Kennedy; A Ickowicz; T Pathare; M Malone; R Schachar; C L Barr
Journal:  Genes Brain Behav       Date:  2006-09-08       Impact factor: 3.449

7.  An application of analyzing the trajectories of two disorders: A parallel piecewise growth model of substance use and attention-deficit/hyperactivity disorder.

Authors:  Mary Rose Mamey; Celestina Barbosa-Leiker; Sterling McPherson; G Leonard Burns; Craig Parks; John Roll
Journal:  Exp Clin Psychopharmacol       Date:  2015-09-21       Impact factor: 3.157

8.  Pharmacist Medication Management of Adults with Attention Deficit: An Alternative Clinical Structure.

Authors:  Rex Huang; Samuel J Ridout; Brooke Harris; Kathryn K Ridout; Kavitha Raja
Journal:  Perm J       Date:  2020-03-18

9.  Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers.

Authors:  Suma M Krishnan; Michael Pennick; Jeffrey G Stark
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

10.  Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder.

Authors:  Lenard A Adler; David Goodman; Richard Weisler; Mohamed Hamdani; Thomas Roth
Journal:  Behav Brain Funct       Date:  2009-08-03       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.